Saladax Biomedical, Inc. has announced the U.S. launch of the MyCare(TM) portfolio of exposure optimization tests. The MyCare portfolio is comprised of simple blood tests that provide oncologists with specific information about each patient’s exposure to chemotherapy, to help the doctor make informed decisions on drug dose adjustments, with the goals of maximizing the therapy’s effectiveness and limiting its potential side effects. Read more: http://online.wsj.com/article/PR-CO-20130619-905911.html?mod=googlenews_wsj
Client & Alumni News
Ben Franklin Client Saladax Announces U.S. Launch of MyCare(TM) Chemotherapy Exposure Optimization Tests
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.